[go: up one dir, main page]

DK1148875T3 - Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer - Google Patents

Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer

Info

Publication number
DK1148875T3
DK1148875T3 DK00903441T DK00903441T DK1148875T3 DK 1148875 T3 DK1148875 T3 DK 1148875T3 DK 00903441 T DK00903441 T DK 00903441T DK 00903441 T DK00903441 T DK 00903441T DK 1148875 T3 DK1148875 T3 DK 1148875T3
Authority
DK
Denmark
Prior art keywords
compositions
increasing
methods
blood cells
white blood
Prior art date
Application number
DK00903441T
Other languages
English (en)
Inventor
Ronald Trevor Macfarland
Andrew W Miller
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of DK1148875T3 publication Critical patent/DK1148875T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00903441T 1999-02-02 2000-02-02 Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer DK1148875T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02
PCT/CA2000/000104 WO2000045814A1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
EP00903441A EP1148875B1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count

Publications (1)

Publication Number Publication Date
DK1148875T3 true DK1148875T3 (da) 2004-10-18

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00903441T DK1148875T3 (da) 1999-02-02 2000-02-02 Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer

Country Status (24)

Country Link
US (2) US6365583B1 (da)
EP (1) EP1148875B1 (da)
JP (2) JP4968868B2 (da)
KR (1) KR100643553B1 (da)
CN (1) CN1310642C (da)
AP (1) AP1497A (da)
AT (1) ATE268597T1 (da)
AU (2) AU772979B2 (da)
BR (1) BR0007924A (da)
CA (1) CA2361587C (da)
CZ (1) CZ20012698A3 (da)
DE (1) DE60011391T2 (da)
DK (1) DK1148875T3 (da)
ES (1) ES2222174T3 (da)
HK (1) HK1038319B (da)
HU (1) HUP0200100A3 (da)
IL (1) IL144400A (da)
MX (1) MXPA01007801A (da)
NO (1) NO20013770L (da)
NZ (1) NZ513602A (da)
PT (1) PT1148875E (da)
SI (1) SI1148875T1 (da)
TR (1) TR200102239T2 (da)
WO (1) WO2000045814A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6667320B2 (en) * 1999-12-17 2003-12-23 Anormed Chemokine receptor binding heterocyclic compounds
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
BR0113931A (pt) * 2000-09-15 2004-01-13 Anormed Inc Compostos heterocìclicos ligantes receptores de quimiocinas
IL154229A0 (en) 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
EP1411918B1 (en) * 2001-07-31 2011-12-28 Genzyme Global S.à.r.l. Methods to mobilize progenitor/stem cells
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP1487795B1 (en) * 2001-09-12 2010-11-03 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2325387C2 (ru) * 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
NZ542850A (en) * 2003-04-22 2007-12-21 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7491735B2 (en) * 2003-12-11 2009-02-17 Genzyme Corporation Chemokine receptor binding compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
WO2006020891A2 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US7790747B2 (en) * 2005-06-15 2010-09-07 Genzyme Corporation Chemokine receptor binding compounds
BRPI0614801A2 (pt) * 2005-08-16 2009-05-19 Genzyme Corp compostos de ligação a receptor de quimiocina
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
RU2009107030A (ru) * 2006-08-02 2010-09-10 Джензим Корпорейшн (Us) Комбинированная терапия
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
WO2008075369A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
KR101719339B1 (ko) 2009-06-14 2017-03-23 바이오카인 테라퓨틱스 리미티드 혈소판 수준을 증가시키는 펩타이드 요법
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX365242B (es) * 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
CN115887671A (zh) 2015-07-16 2023-04-04 百欧肯治疗有限公司 治疗癌症的组合物及方法
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN109187337A (zh) * 2018-09-10 2019-01-11 南京工业职业技术学院 一种筛选强韧性FeAl晶界的方法
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
DE69929464T2 (de) * 1998-11-17 2006-09-07 Smithkline Beecham Corp. Zyklische polyamine zur behandlung der thrombozytopenie

Also Published As

Publication number Publication date
AU2004203847A1 (en) 2004-09-09
CA2361587C (en) 2010-04-20
TR200102239T2 (tr) 2002-01-21
HK1038319B (en) 2005-03-18
HK1038319A1 (en) 2002-03-15
SI1148875T1 (en) 2004-12-31
DE60011391D1 (de) 2004-07-15
IL144400A0 (en) 2002-05-23
HUP0200100A2 (hu) 2002-05-29
WO2000045814A1 (en) 2000-08-10
AP1497A (en) 2005-11-20
AP2001002221A0 (en) 2001-09-30
US20020058653A1 (en) 2002-05-16
ATE268597T1 (de) 2004-06-15
AU772979B2 (en) 2004-05-13
NO20013770L (no) 2001-09-27
CZ20012698A3 (cs) 2002-03-13
EP1148875B1 (en) 2004-06-09
JP2002536329A (ja) 2002-10-29
US6670354B2 (en) 2003-12-30
PT1148875E (pt) 2004-10-29
JP2011088937A (ja) 2011-05-06
EP1148875A1 (en) 2001-10-31
NZ513602A (en) 2003-10-31
AU2004203847B2 (en) 2007-03-22
CN1338933A (zh) 2002-03-06
US6365583B1 (en) 2002-04-02
CN1310642C (zh) 2007-04-18
MXPA01007801A (es) 2003-06-04
IL144400A (en) 2010-05-17
CA2361587A1 (en) 2000-08-10
HUP0200100A3 (en) 2004-07-28
JP4968868B2 (ja) 2012-07-04
ES2222174T3 (es) 2005-02-01
NO20013770D0 (no) 2001-08-01
KR20010101896A (ko) 2001-11-15
AU2527800A (en) 2000-08-25
KR100643553B1 (ko) 2006-11-10
DE60011391T2 (de) 2005-07-14
BR0007924A (pt) 2001-11-06

Similar Documents

Publication Publication Date Title
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK0958838T3 (da) Fremgangsmåde til fjernelse af hvide blodlegemer
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
NO20005828L (no) Herdbare punktfluidsammensetninger og fremgangsmåter
ATE388677T1 (de) Zwischenwirbelimplantat
ATE357459T1 (de) Antikörper gegen mensliches il-12
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
FR2780269B1 (fr) Implant rachidien
DK1360287T3 (da) Fremgangsmåder til modifikation af eukaryotiske celler
DE50010727D1 (de) Flächiges Implantat
DK1437106T3 (da) Prøveimplantatsæt
DK1242095T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK0969846T4 (da) Sammensætninger og fremgangsmåder til reduktion af okulær hypertension
DK1114641T3 (da) Fluorethersammensætninger og metoder til inhibering af deres nedbrydning i nærværelse af en Lewis-syre
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
NO20021786L (no) Skumdempningsfremgangsmåter og sammensetninger
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK199800837A (da) Anlæg til behandling af emner
DE69936639D1 (de) Stimmprothese
DK1620058T3 (da) Sammensætning til forbedring af kognition og hukommelse
DK1702623T3 (da) Anvendelse af interferon-gamma til behandling af hjertehypertrofi